Study shows at least one urologic complication was experienced during the course of seven years.
Read More »Yearly Archives: 2018
Using Electricity to Cure Type 2 Diabetes
Can neuromodulation prevent the onset of metabolic dysfunction associated with the onset of diabetes?
Read More »CGM Candidates
In your opinion, which diabetes patients are the best candidates for CGM?
- Patients on more than five diabetes medications
- Patients unable to achieve their HbA1c goal despite focused efforts
- Patients with frequent or extreme glucose excursions (>200 mg/dL, within day or day-to-day)
- or All of the above?
Follow the link to see how you and your colleagues compare.
Read More »Subjective Cognitive Decline
What proportion of Americans age 45 y and older have self-reported memory problems?
A. 1 in 30B. 1 in 16
C. 1 in 9
D. 1 in 4
Follow the link for the answer.
Read More »HbA1c Variability Is a Strong Predictor of Mortality in T2DM
HbA1c variability is a powerful, independent measure, regardless of how it is measured
Read More »Gestational Diabetes Tied to Subsequent Glucose Disorders
Long-term effects seen in mothers, but offspring not significantly overweight, obese
Read More »Study Provides Estimates of U.S. Prevalence of Type 1, 2 Diabetes
Prevalence of type 1 diabetes 0.5 percent, type 2 diabetes 8.5 percent among U.S. adults
Read More »Scott Isaacs 2018 Transcript
In this Exclusive Interview transcript, Scott Isaacs talks with Diabetes in Control Medical Editor Joy Pape during the AACE 2018 convention in Boston about using meal replacements for obesity treatment.
Read More »How To Give A Painless Injection
How to give a painless injection? If you have Type 2 diabetes, sooner or later you may require insulin injections, either temporarily (as during infections) or permanently. This is nothing to be afraid of, even though many people with long-standing Type 2 diabetes literally spend years worrying about it.
Read More »SGLT2 Inhibitors: A New Class of Diabetes Medications
What is a SGLT2 Inhibitor? Sodium-glucose co-transporter 2 (SGLT2) inhibitors, also called gliflozin drugs, are a new class of diabetic medications indicated for the treatment of type 2 diabetes. They have also been found to show cardiac benefits in patients with diabetes, and are being studied for possible use in type 1 diabetes. They work by reducing the absorption of glucose via the kidneys so that excess glucose is excreted through urination.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.